Reumon Gel

Quick links

Choose a section

Quick links to important sections

Advertisements

Reumon Gel

Selected form

Advertisements
Advertisements

Overview of Reumon Gel

Quick Facts

Property Description
Active ingredient Etofenamate (INN)
Form Gel (Topical preparation)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose Local anti-inflammatory and analgesic action
Origin Synthetic compound (Anthranilic acid derivative)

Reumon Gel: Identity, Form, and Pharmacological Class

Reumon Gel is a brand-name topical pharmaceutical preparation containing the active ingredient Etofenamate, and it is formally classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This medicine is specifically formulated as a gel, which distinguishes it as a dermal product intended for targeted application directly to the skin. The product is typically available over the counter (OTC) in many regions, emphasizing its role in self-managed care for common muscle and joint discomfort.

This single-active-ingredient preparation utilizes a topical route of administration, allowing the anti-inflammatory action to be highly focused on a specific, localized area. Etofenamate exhibits high penetration capabilities in topical forms, which means the medicine can reach the underlying painful tissues.

Composition and General Therapeutic Benefit

The medicine’s entire therapeutic effect is derived from its sole active compound, Etofenamate, which is a synthetic compound chemically classified as an anthranilic acid derivative. The gel itself is formulated using a specialized hydrogel base which acts as the vehicle, enabling the transfer of Etofenamate across the skin barrier.

The general purpose of Reumon Gel is to provide targeted, localized relief from inflammation and pain. By utilizing the mechanism characteristic of its pharmacological class, it provides a local anti-inflammatory effect and a local analgesic effect at the site of application. Topical etofenamate is used for the treatment of localized inflammatory conditions to reduce both inflammation and associated pain where applied, making it useful for providing comfort and supporting recovery in muscle and joint areas.

Advertisements

What side effects are possible with Reumon Gel?

Possible Side Effects and Safety Information

The safety profile for Reumon Gel (topical Etofenamate) is primarily characterized by localized reactions at the application site due to the dermal route of administration. Adverse effects are formally classified by frequency according to regulatory documentation.


Frequency-Classified Adverse Reactions

The majority of documented reactions involve the skin, classified as follows in regulatory summaries:

Frequency Category Documented Adverse Reaction (Regulatory Terminology)
Common (≥ 1/100 to < 1/10) Pruritus (Itching), Erythema (Redness), Local irritation
Rare (≥ 1/10,000 to < 1/1,000) Contact dermatitis, Allergic dermatitis, Photosensitive dermatitis
Very Rare (< 1/10,000) Urticaria (Hives), Bullous reactions, Systemic Hypersensitivity Reactions

Systemic and Population Safety

While focused on the Skin and Subcutaneous Tissue Disorders, the possibility of systemic effects cannot be entirely excluded due to cutaneous absorption of the active substance, with the risk increasing based on the size of the treated surface area and exposure time. This includes the potential for Very Rare but serious adverse reactions, such as Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN), which are documented high-level concerns for the NSAID pharmacological class.

Regarding specific populations, use of the gel is not recommended in children or infants, or during pregnancy and lactation, as dedicated safety studies are not available for these groups. Official safety constraints also mandate that the application site must be protected from sun exposure to avoid the risk of contact photosensitivity. The risk of severe cutaneous reactions is documented as highest during the first month of treatment.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Reumon Gel

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations: Overdosage is not considered a practical possibility through the intended topical route of administration.
Physiological systems affected (as stated in label): Systemic manifestations are confined to the event of accidental oral ingestion, potentially involving gastrointestinal and central nervous system effects consistent with systemic NSAID exposure.
Dose-related or exposure-related factors (if applicable): Risk of toxicity is associated with accidental ingestion of the entire tube contents, not routine dermal application.
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention for any suspected overdose or accidental ingestion, particularly in children.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): The intended topical use carries an officially documented negligible risk of overdose.
Regulatory basis: Primarily based on Summary of Product Characteristics (SmPC) documentation.
Overdose-context constraints (as defined in official documents): The necessary intervention scenario is constrained to accidental oral ingestion, for which no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • The official prescribing information states that overdosage is not a practical possibility through the dermal route.
  • Seek immediate medical attention is the mandated action for any suspected overdose, especially if the product is accidentally swallowed.
  • In cases of acute systemic overexposure, the required action is symptomatic and supportive treatment.

Connection to the overall overdose profile (3 sentences): The regulatory documents explicitly define the overdose profile by establishing that the risk of overdose from the product's intended dermal application is negligible. The emergency-seeking conditions are therefore strictly focused on the low-probability, high-risk event of accidental oral ingestion, triggering mandated regulatory procedures. This ensures the communication remains strictly aligned with the official label text on emergency response.

Advertisements

Therapeutic Uses of Reumon Gel

What Reumon Gel Treats: Main Uses and Benefits

Reumon Gel (Etofenamate topical) is an analgesic and anti-inflammatory formulation generally applied in addressing discomfort originating from the soft tissues of the body's locomotor system. Its primary therapeutic purpose is to provide symptomatic relief where discomfort is localized. The formulation is used in clinical areas where symptomatic support for musculoskeletal issues is required.


The gel is commonly used in clinical settings for managing symptoms associated with several conditions, including acute muscle strains, ligament sprains, contusions (bruises), tendonitis, and localized forms of osteoarthritis. This use assists in addressing symptom clusters that may become intense or disruptive, such as sudden localized pain and swelling.

“The symptomatic benefit offers supportive relief that helps patients cope more steadily with difficult, episodic discomfort in affected tissues.”

It is often applied during phases when symptoms become more noticeable, such as in post-traumatic scenarios or during flare-ups of chronic discomfort. This use provides support that helps ease the overall symptom burden of persistent, localized pain on functional stability.


Quick Fact: Symptom Management Focus
Common Clinical Contexts: Used in contexts involving acute soft-tissue trauma and non-articular rheumatic conditions.
Symptoms Addressed: Localized Pain and Swelling associated with strains and overuse syndromes.
Benefit: Supports general well-being during symptomatic phases.

Regulatory References

  1. Summary of Product Characteristics (HPRA)
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Reumon Gel — Official Regulatory Information

This eligibility profile is defined by official government-approved labeling and lists specific populations and conditions that determine use.

Eligibility Scope Status as per Regulatory Documents
Populations Allowed Adults (including the elderly) under standard conditions.
Populations Not Recommended Children and Infants; Pregnant Women; Breastfeeding/Lactating Women.
Populations Contraindicated Individuals with hypersensitivity to etofenamate, excipients, other NSAIDs, or aspirin.

Official Eligibility Statements

Official documents define use restrictions based on age, life stage, and the condition of the application site.

  • Use is contraindicated if the skin is damaged, including eczematous surfaces, open wounds, or ulcers. Application is also contraindicated in the presence of a local infection or when using occlusive dressings.
  • The gel is not recommended for children or infants due to a lack of specific studies in the pediatric population.
  • Use is not recommended during pregnancy or lactation, as the safety to the foetus and the suckling infant has not been established.
  • For patients with impaired renal function, some regulatory documents indicate no need to change the recommended dosage, while specific recommendations for hepatic impairment are often unavailable due to a lack of sufficient studies.

Connection to the overall eligibility profile The regulatory documents strictly limit the use of Reumon Gel primarily through absolute contraindications tied to allergic history and the integrity of the application site. For populations such as children and pregnant/lactating women, use is formally not recommended, which confines eligibility to the standard adult population under standard conditions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Reumon Gel (etofenamate) is a non-steroidal anti-inflammatory drug (NSAID) formulated for topical application. Official regulatory documentation indicates that the risk of drug-drug interactions is minimal when the gel is used as directed, due to the low systemic absorption of the active ingredient through the skin.

Documented Interaction Profile

Interaction Domain Official Regulatory Requirement/Note
Systemic NSAIDs and Analgesics The potential for additive systemic effects exists if the gel is applied over large skin areas or for extended periods. This may theoretically increase the risks associated with concurrently administered oral NSAIDs.
Anticoagulant Therapy While clinical studies have not indicated a need for dosage modification of the gel in patients undergoing anticoagulant therapy, caution is advised. The minimal systemic absorption means the risk of interaction is low under standard use.
Route of Administration Constraint Regulatory documents caution that using the gel on large areas of damaged skin or for prolonged periods may increase systemic exposure, thereby increasing the theoretical potential for interactions that are characteristic of oral NSAIDs.

The interaction profile of this topical product is structured around its physical properties, specifically the minimal entry of etofenamate into the bloodstream. This characteristic differentiates its interaction considerations significantly from those of oral NSAID formulations. No specific timing rules or contraindications based solely on drug-drug interactions are defined, provided the application remains localized and short-term.

Advertisements

Mechanism of Action

Inhibition of Prostaglandin Synthesis


The core mechanism of Etofenamate is the non-selective inhibition of Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, the molecule restricts the Arachidonic Acid Cascade, thereby significantly reducing the local production of pro-inflammatory mediators, primarily prostaglandins. This action modifies the early molecular steps that shape the acute response, contributing to the reduction of localized fluid leakage and modulation of local microvascular dynamics.

Localized Suppression of Nociceptive Pathways


The mechanism involves a coordinated action that modulates the activity of peripheral nociceptive pathways. Etofenamate possesses an ancillary ability to antagonize Bradykinin, a potent chemical irritant, at its local receptors. Furthermore, it stabilizes lysosomal membranes within cells, limiting the release of enzymes that would otherwise perpetuate the inflammatory cycle. These combined actions attenuate the sensitization of peripheral nociceptors, which restricts the physiological consequence of elevated mediator concentrations.

Constraint by Topical Application


Due to the topical administration, the NSAID mechanism is highly focused on peripheral pathways in the soft tissues (muscle, tendon, fascia) underlying the application site. This geographical constraint defines the scope of the mechanism, which is limited to modulating localized physiological responses rather than systemic ones.

Advertisements

Dosage and Administration Information

How to Use Reumon Gel

Reumon Gel, which contains the active substance Etofenamate, is designated for topical administration, meaning it is applied directly to the skin. The usage protocol includes specific application techniques, dosing measurements, and limitations on the duration of use.


Official Administration Protocol

Usage Aspect Standard Usage Details
Route & Form Applied cutaneously (to the skin) as a topical gel preparation.
Dosing Regimen A strip of gel measuring 5 to 10 cm (5% w/w strength) or 2.5 to 5 cm (10% w/w strength) is used per application, adjusted to the size of the area being treated.
Frequency Application is typically performed up to 3 to 4 times daily, depending on the formulation strength and condition being addressed.
Duration Limit Treatment should generally not exceed 14 days for acute conditions, with a maximum limit of six weeks of continuous use. Therapy for osteoarthritis is reviewed after four weeks.

Application Technique and Population Rules

When applying the gel, the measured quantity must be gently rubbed in until the product has largely penetrated the skin. It is established that the medicine is for external use only and that hands should be thoroughly washed following application to prevent unintended transfer.

Standard adult regimens are generally applicable as there are no specific dosage adjustments required for older adults or for patients with renal or hepatic impairment. However, the use of Etofenamate topical gel is not recommended for children or infants due to a lack of specific data regarding its administration in these populations. Finally, the product is prohibited from being used with occlusive dressings.

Advertisements

Recent Clinical Evidence

Reumon Gel: Research Evidence Overview


Evidence for Use in Acute Soft-Tissue Injuries

Research exploring Reumon Gel (topical etofenamate) for conditions like sprains, strains, and contusions is structured around short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily involve adult patients with recent-onset trauma. Researchers explored short-term symptom changes by monitoring the difference in pain on movement between those using the active gel and those using a non-medicated gel (placebo).

Studies reported measurements of patterns observed when comparing the active gel to the non-medicated gel over short observation periods. Research highlights changes measured during the study period where trials reported that the active treatment groups were compared to placebo groups based on measurements of patient-reported outcomes describing perceived discomfort. These studies generally focus on outcomes over the first one to two weeks of use.


Evidence for Chronic Localized Musculoskeletal Conditions

Studies examining the gel's profile in chronic localized conditions, such as certain forms of osteoarthritis and persistent soft-tissue discomfort, also include RCTs and systematic reviews. This research focused on outcomes related to systemic or functional imbalance, such as changes in overall joint pain and measures of daily functioning or activity level in adult patients.

Findings describe patterns of difference between the active gel and placebo groups based on measurements of pain and functional scores. Topical etofenamate was examined in research contexts that also studied orally administered non-steroidal anti-inflammatory drugs (NSAIDs). These studies observed responses over defined time intervals, with follow-up durations sometimes extending up to 8 to 12 weeks.


Research Gaps and Areas of Uncertainty

Key limitations in the overall research structure include the suggestion that research comparing outcomes against other similar topical non-steroidal anti-inflammatory drugs is limited. Furthermore, long-term effects are not fully established, as the follow-up durations were limited in the core trials. Data for certain groups, such as pediatric populations (children) or specific elderly age groups, remain insufficient.

Key Studies & References Summary of Product Characteristics - Etoflam 10% w/w gel (Etofenamate)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Reumon Gel (FAQ)

Q: Is Reumon Gel available without a prescription?

A: According to official documentation, Reumon Gel (etofenamate) is generally classified as a Non-Prescription Medicine or has equivalent over-the-counter status in many regions where it is authorized. This indicates its typical availability for self-managed care without a doctor’s prescription.


Q: Is Reumon Gel the same as ibuprofen gel?

A: No, Reumon Gel is not the same as ibuprofen gel. While both are classified as non-steroidal anti-inflammatory drugs (NSAIDs), the active ingredient in Reumon Gel is Etofenamate. The active ingredient in Reumon Gel, Etofenamate, is chemically distinct from ibuprofen.


Q: How long does it take to feel the effects of Reumon Gel?

A: Official clinical reviews of topical etofenamate, such as those conducted for acute injuries, have observed significant reductions in pain on movement starting from time points such as 48 to 72 hours after the first application in study participants. Symptomatic relief is measured in research contexts over a short-term period.


Q: Can Reumon Gel be used for long-term pain management?

A: Official documentation restricts use to limited periods; for instance, the continuous use limit is generally six weeks maximum. Treatment for chronic conditions is often reviewed after four weeks, according to regulatory documents. Use of the product is not authorized for indefinite or long-term pain management.


Q: Is Reumon Gel safe to use every day?

A: The labeling for Reumon Gel includes restrictions on both the frequency of application and the overall duration of use. It is noted in safety documents that the potential for systemic absorption and related effects is associated with application over large areas of skin or for extended periods.


Q: Can I use Reumon Gel on my back pain?

A: The official therapeutic indications state that the product is intended for the local symptomatic treatment of pain, inflammation, and swelling in soft tissue injuries. The therapeutic indication covers local musculoskeletal pain areas, consistent with the product’s design to focus anti-inflammatory action on peripheral tissues underlying the application site.


Q: Is Reumon Gel appropriate for muscle soreness after exercise?

A: Official documents indicate that the product is used for the treatment of acute soft tissue injuries such as sprains, strains, and contusions. This purpose is consistent with addressing localized muscle pain or soreness that may be associated with minor tissue strain.


Q: Why do people use Reumon Gel for joint stiffness?

A: The product is indicated for the local relief of inflammation and pain. As Etofenamate is an anti-inflammatory drug, its intended action is to relieve discomfort that may be associated with stiffness in conditions like osteoarthritis, which is mentioned in research overviews.


Q: Can Reumon Gel affect blood pressure medication?

A: While specific interactions for the topical gel are minimal due to low systemic absorption, regulatory information advises caution because NSAIDs, as a class, may theoretically decrease the antihypertensive activity of certain medications. The potential for this risk is noted to increase in situations involving high or prolonged use of the gel.


Q: What happens if I apply too much Reumon Gel?

A: Official regulatory documents state that overdosage is not a practical possibility when the product is used as directed for topical application. In the event of accidental swallowing, prompt medical consultation is necessary.


Q: Can Reumon Gel cause digestive problems?

A: Gastrointestinal side effects are not listed among the common adverse reactions for the topical gel. However, since the possibility of systemic NSAID side effects (which include GI issues) cannot be entirely excluded, this risk is primarily associated with use over large application areas or for prolonged periods.


Q: Are there any specific safety concerns for patients with asthma using Reumon Gel?

A: Use of the gel is contraindicated (officially prohibited) in patients with a known hypersensitivity to the active substance, other NSAIDs, or to acetylsalicylic acid (aspirin). The contraindication is based on the risk of hypersensitivity reactions, which, for NSAIDs as a class, often includes the potential for bronchospasm in aspirin-sensitive individuals.


Q: Can people with sensitive skin use Reumon Gel?

A: Local skin reactions such as pruritus (itching), erythema (redness), and local irritation are listed as Common side effects in official safety documents. Furthermore, the product should not be used on broken, damaged, or eczematous skin. Patients concerned about sensitive skin are directed to consult the product's official contraindications.


Q: Are there studies comparing Reumon Gel's absorption to oral NSAIDs?

A: Regulatory documents and supporting clinical reviews confirm that the level of the drug in the bloodstream from topical NSAIDs is very much lower than with the same drug taken orally. The low systemic absorption is a characteristic of the topical formulation, which is considered in relation to the potential for systemic effects.


Q: How long does the pain relief from Reumon Gel typically last?

A: The application frequency, as designated in official labeling, suggests an expected duration of symptomatic relief. Based on the dosing interval indicated in official product labeling, the expected duration of sufficient symptomatic relief is generally aligned with a standard clinical interval of 6 to 8 hours per application.


Q: Does Reumon Gel have a strong smell?

A: Patient Information Leaflets describe the product as a nearly transparent, yellowish gel. The formulation includes isopropyl alcohol as an excipient, which may temporarily impart an odor, though this is not formally categorized as an adverse effect or safety concern.


Q: What is the official guidance on using Reumon Gel near the eyes?

A: Official product information states that the gel is for external use only and that contact with the eyes or other mucus membranes should be avoided. If accidental contact occurs, the affected area should be washed immediately.


Q: Can Reumon Gel interfere with other topical products?

A: Yes, official documents explicitly list a contraindication (prohibition of use) against applying Reumon Gel simultaneously to the same site with any other topical preparation. This restriction is documented as a contraindication in the official product information.


Q: Is it normal to feel a tingling sensation after applying Reumon Gel?

A: While local irritation is listed as a Common side effect in regulatory documents, which might be interpreted by users as a tingling sensation, a specific description of tingling (paresthesia) is not typically listed in the frequency tables of documented adverse reactions.


Q: Are there any reported long-term side effects from Reumon Gel?

A: Official guidelines impose limitations on the duration of use. Furthermore, regulatory reviews also note a lack of specific data on reactions associated with long-term use due to the limited follow-up periods in the core clinical trials that support the drug's authorization.


Q: Can Reumon Gel be used for neck pain?

A: The product is indicated for the local symptomatic treatment of pain, inflammation, and swelling in soft tissue injuries and joint diseases. The therapeutic indication covers local musculoskeletal pain areas, consistent with the product’s design to focus action on the application site.


Q: What are the non-medicinal ingredients in Reumon Gel?

A: Official product information, such as the Summary of Product Characteristics, lists the non-medicinal ingredients (excipients) used in the formulation. These typically include, but are not limited to, isopropyl alcohol, macrogol 400, sodium hydroxide, and the hydrogel base components.

Advertisements

How should Reumon Gel be stored and disposed of?

Storage and Disposal Requirements for Reumon Gel

Reumon Gel (etofenamate) must be stored under specific regulatory conditions to maintain its effectiveness and stability. The medicine must be stored at a temperature not exceeding 25°C and is officially directed not to be frozen.

Storage Conditions

Requirement Rule
Temperature Do not store above 25 C; do not freeze.
Protection Store in the original package to protect from light and keep the container tightly closed.
Stability Use within 6 months after the first opening of the tube.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal

Unused or expired gel must not be thrown away in household waste or via wastewater. Regulatory documents require consumers to ask a pharmacist how to dispose of the medicine to ensure it is handled and discarded according to applicable environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reumon Gel found in:

A-Z Index: